1Progress in clinical trials of cell transplantation for the treatment of spinal cord injury: how many questions remain unanswered?Xu-Chang Hu, Yu-Bao Lu, Yong-Na Yang, Xue-Wen Kang, Yong-Gang Wang, Bing Ma, Shuai Xing405-4132Postnatal therapeutic approaches in genetic neurodevelopmental disordersGilad Levy, Boaz Barak414-4223Regulation of neuroimmune processes by damage- and resolution-associated molecular patternsAndis Klegeris423-4294Neonatal opioid exposure: public health crisis and novel neuroinflammatory diseaseVikram Vasan, Yuma Kitase, Jessie C. Newville, Shenandoah Robinson, Gwendolyn Gerner, V. Joanna Burto, Lauren L. Jantzie430-4325Physiopathology of ischemic stroke and its modulation using memantine: evidence from preclinical strokeHilda Martínez-Coria, Isabel Arrieta-Cruz, María-Esther Cruz, Héctor E. López-Valdés433-4396MicroRNAs as diagnostic and prognostic biomarkers of age-related macular degeneration: advances and limitationsBridget Martinez, Philip V. Peplow440-4477Targeting the core of neurodegeneration: FoxO, mTOR, and SIRT1Kenneth Maiese448-4558Microglial activation and adult neurogenesis after brain strokeIjair R.C. dos Santos, Michelle Nerissa C. Dias, Walace Gomes-Leal456-4599The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′,5′-monophosphate (Epac) for central nervous system traumaAlba Guijarro-Belmar, Dominik Mateusz Domanski, Xuenong Bo, Derryck Shewan, Wenlong Huang460-46910Role of vitamin B12 deficiency in ischemic stroke risk and outcomeGyllian B. Yahn, Jamie E. Abato, Nafisa M. Jadavji470-47411Current scenario of the genetic testing for rare neurological disorders exploiting next generation sequencingChiara Di Resta, Giovanni Battista Pipitone, Paola Carrera, Maurizio Ferrari475-48112Connexin therapeutics: blocking connexin hemichannel pores is distinct from blocking pannexin channels or gap junctionsMonica L. Acosta, Mohd N. Mat Nor, Cindy X. Guo, Odunayo O. Mugisho, Frazer P. Coutinho, Ilva D. Rupenthal, Colin R. Green482-48813Saccharomyces cerevisiae in neuroscience: how unicellular organism helps to better understand prion protein?Takao Ishikawa489-49514Neurogenesis versus neurodegeneration: the broken balance in Alzheimer's diseaseBaruh Polis, Abraham O. Samson496-49715Is serine racemase (SRR) a second hit target for LRRK2-G2019S induced Parkinson's disease?Sarah Louise Nickels, Jens Christian Schwamborn498-49916Targeting mechanisms in cognitive training for neurodegenerative diseasesAnnalena Venneri, Riccardo Manca, Linford Fernandes, Oliver Bandmann, Matteo De Marco500-50117Targeting metabolism to treat multiple sclerosisPavan Bhargava502-50318Brain angiotensin Ⅱ in dopaminergic imbalance-derived pathologies:neuroinflammation and vascular responsesVictoria Belén Occhieppo, Osvaldo Martin Basmadjian, Claudia Bregonzio504-50519Dysfunction of axonal transport in normal-tension glaucoma: a biomarker of disease progression and a potential therapeutic targetKazuyuki Hirooka, Tohru Yamamoto, Yoshiaki Kiuchi506-50720Continued development of azithromycin as a neuroprotective therapeutic for the treatment of spinal cord injury and other neurological conditionsTimothy J. Kopper, John C. Gensel508-509 